Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

44.51 -0.14 (-0.32%)
Streaming Delayed Price Updated: 9:49 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗
RPRX stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout above key resistance. 
Via Chartmill
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
News headline image
2 Reasons to Avoid RPRX and 1 Stock to Buy Instead
While the S&P 500 is up 23.9% since April 2025, Royalty Pharma (currently trading at $36.80 per share) has lagged behind, posting a return of 12.5%. This was partly due to its softer quarterly results... 
Via StockStory
Topics Government Stocks Supply Chain
News headline image
How Do Investors Really Feel About Royalty Pharma? ↗
 
Via Benzinga
News headline image
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗
Via MarketBeat
News headline image
Royalty Pharma Declares Fourth Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Economy Stocks
News headline image
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Topics Economy
News headline image
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
From Zenas BioPharma
Via GlobeNewswire
News headline image
1 of Wall Street’s Favorite Stock to Keep an Eye On and 2 We Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up ↗
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
News headline image
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Value Stock with Exciting Potential and 2 We Avoid
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings ↗
Royalty Pharma (RPRX) shows strong breakout potential with high technical and setup ratings, solid trend consistency, and clear support levels. Ideal for traders eyeing momentum stocks. 
Via Chartmill
News headline image
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
News headline image
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.7% year on year to $578.7 million. Its non-GAAP profit of $1.14... 
Via StockStory
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Royalty Pharma (RPRX) Q2 Receipts Up 20% ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.